Biocon Biologics
Transforming Healthcare. Transforming Lives.

FACTSHEET

TRANFORMING HEALTHCARE. TRANSFORMING LIVES.

Biocon Biologics, headquartered in Bengaluru, India, is a leading global biosimilars company with several in-market and in-development biosimilars including monoclonal antibodies for cancer and autoimmune diseases, insulin and insulin analogs for diabetes and conjugated recombinant proteins. It has a strong research pipeline of biosimilar molecules across diabetes, oncology, immunology, and other non-communicable diseases and many firsts to its credit, including being the first globally to receive approval for a biosimilar Trastuzumab, as well as, an 'interchangeable biosimilar' approval for its Insulin Glargine from the U.S. Food and Drug Administration. The Company is leveraging cutting-edge science, innovative tech platforms and advanced research & development capabilities to lower treatment costs while improving healthcare outcomes. Eight molecules from Biocon Biologics' portfolio have been taken from lab to market in developed markets like U.S., EU, Australia, Canada and Japan, as well as, in emerging markets. Biocon Biologics is acquiring its partner Viatris' global biosimilars business to create a unique, fully integrated, world leading biosimilars enterprise. It also has a strategic alliance with Serum Institute Life Sciences to address the inequitable access to life saving vaccines and biologics globally.

Biocon Biologics is a subsidiary of Biocon Ltd.

Capabilities Built on Advanced Technologies

Ecosystem Focused on Operational Excellence to Address Patients' Needs Globally

BIOCON BIOLOGICS: AT A GLANCE

75+
Countries where BBL's products are available

5,000+
High-quality, diverse talent pool

3
Manufacturing sites (2 Bengaluru, 1 Malaysia)

4
Global Development Partnerships (Viatris, Sandoz, Adagio, Serum Institute Life Sciences)

25+
cGMP approvals from International regulatory agencies

2
R&D sites (Bengaluru, Chennai)

USD 330+
Million raised through PE investments till date

~1000
Patents granted

WORLD CLASS RESEARCH & MANUFACTURING INFRASTRUCTURE

USD 1+ Billion
Invested in building global manufacturing scale for biologics

13th
Rank among Top 25 Global Biopharma Players with >300kL capacity

85,000
sq. ft. state-of-the-art research facility in Bengaluru

60,000
sq. ft. research center in Chennai

>10%
of revenue invested in R&D annually

~400
Scientists & research associates

20%
with MDs or PhD's

PATIENT-CENTRIC INNOVATIVE HEALTHCARE SOLUTIONS

2.75+ Billion
doses of rh-Insulin supplied to people with diabetes globally

5.3 Million*
patients served globally through our biosimilars

20
molecules comprising a comprehensive portfolio of in-market and in-development biosimilars for treating diabetes, cancer, autoimmune disorders and other non-communicable diseases

GLOBAL SCALE MANUFACTURING EXPERTISE

Drug Substance, Drug Product & Devices capabilities

Proprietary *Pichia pastoris* & mammalian CHO and NSO cell-based platforms

Large-scale capacity catering to global needs

Robust regulatory compliance

1st biopharma company from India to win ISPE's 2021 Facility of the Year Honorable Mention Award for mAbs facility

*Number of lives is calculated based on volume supplied; MAT March 2022

SEVERAL FIRSTS TO OUR CREDIT IN THE AREA OF BIOSIMILARS

1st company to get approval and launch an interchangeable biosimilar in U.S.: Insulin Glargine (2021)

1st company from India to have a biosimilar commercialized in U.S.: Pegfilgrastim (2018)

1st company from India to have a biosimilar approved in U.S.: Trastuzumab (2017)

1st company globally to get U.S. FDA approval for biosimilar: Trastuzumab (2017)

1st company from India to commercialize a biosimilar in Japan: Insulin Glargine (2016)

1st company to commercialize recombinant human insulin using proprietary *Pichia pastoris* platform (2004)

BIOCON BIOLOGICS HAS INCREASED ACCESS TO HIGH QUALITY INSULINS IN SEVERAL COUNTRIES

BIOCON BIOLOGICS IS AMONG THE TOP INSULINS PLAYERS GLOBALLY, VERTICALLY INTEGRATED AND COST COMPETITIVE

01 Committed to universal access to rh-insulin by reducing prices for low and middle-income countries (LMIC) to less than **10 US cents/day**

02 rh-Insulin approved in **40+ countries**

03 Insulin Glargine approved in **60+ countries**

04 Independent development program for rh-insulin for the **US market**

05 Served **~1.7 million** people with diabetes in India with insulins

COMPREHENSIVE BIOSIMILARS PORTFOLIO CATERING TO PATIENTS' NEEDS WORLDWIDE

CANCER	DIABETES	AUTOIMMUNE DISEASES
Molecule: **Trastuzumab**	Molecule: **Insulin Glargine**	Molecule: **Adalimumab#**
Markets: **U.S., EU, Canada, Australia & selected MoW markets**	Markets: **U.S.^, EU, Australia, Japan & selected MoW markets**	Markets: **EU, Canada & Japan**
Molecule: **Pegfilgrastim**	Molecule: **rh-Insulin**	Molecule: **Etanercept#**
Markets: **U.S., EU, Canada, Australia & selected MoW markets**	Markets: **India, Malaysia, Mexico & other MoW markets**	Markets: **EU**
Molecule: **Bevacizumab**		
Markets: **EU, Australia, India, Malaysia & Canada**		

^ Interchangeable biosimilar Glargine launched in U.S.
# in-licensed product

Fact Sheet last updated on June 2022

Biocon Biologics Limited
Biocon House, Semicon Park, Electronics City, Phase - II, Hosur Road, Bengaluru, Karnataka 560 100. India
Telephone: +91 80 6775 6775. Email: Group.Communications@biocon.com | Website: www.biocon.com

Follow us at